About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Ovarian Epithelial Cancer Treatment
BackgroundIncidence and mortalityOvarian cancer is the fifth leading cause of cancer death among women in the United States and has the highest mortality rate of all gynecologic cancers. It is estimated that 22,240 new cases of ovarian cancer will be diagnosed in the United States in 2013, and 14,030 women will die of this disease. The median age at diagnosis is 63 years. The prognosis for survival from ovarian cancer largely depends on the extent of disease at diagnosis, which is usually advanced, with only about 15% of women presenting with localized disease at diagnosis.[1,2]From 2005 to 2009, incidence rates decreased by 0.9% per year, and mortality rates decreased by 2.0% per year.Ovarian cancer is rare; the lifetime risk of being diagnosed with ovarian cancer is 1.38%.Types of Ovarian CancerThe term ovarian cancer encompasses a heterogeneous group of malignant tumors of ovarian origin that may arise from germ cells, stromal tissue, or
Note: Separate PDQ summaries on Ovarian Cancer Prevention; Ovarian Epithelial Cancer Treatment; Ovarian Germ Cell Tumor Treatment; and Ovarian Low Malignant Potential Tumor Treatment are also available. Evidence of Benefit or Lack of Benefit Associated with ScreeningSingle-threshold cancer antigen 125 (CA-125) levels and transvaginal ultrasound (TVU)There is solid evidence to indicate that routine screening for ovarian cancer with the serum marker CA-125 and TVU does not result in a decrease in mortality from ovarian cancer.Magnitude of Effect: No reduction in mortalityStudy Design: Evidence obtained from one randomized controlled trial.Internal Validity: Good.Consistency: One trial has evaluated the impact on mortality from ovarian cancer.External Validity: Good.Statement of HarmsBased on solid evidence, routine screening for ovarian cancer results in false-positive test results among 9.6% of those screened; of those with false-positive results who had surgery, the complication rate
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Ovarian Cancer Prevention
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. Changes were made to this summary to match those made to the health professional version.
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of ovarian epithelial cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus